Tanzeum (albiglutide) / GSK - LARVOL DELTA

CER-4-T2D: Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study (clinicaltrials.gov) - P=N/A | N=781430 | Active, not recruiting | Sponsor: Brigham and Women's Hospital | Trial completion date: Jul 2024 ➔ Jul 2026 | Trial primary completion date: Jul 2024 ➔ Jan 2026

HEOR • Trial completion date • Trial primary completion date • Cardiovascular • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Cardiorenal Safety Markers With Injectable Glucagon-Like Peptide-1 (GLP-1) Agonists in Type 2 Diabetes: A Network Meta-Analysis. (PubMed, Cureus) - "Efpeglenatide ranked highest for both MACE (OR: 0.74; 95% CI: 0.62-0.87; SUCRA: 81.5%) and renal outcomes (OR: 0.68; 95% CI: 0.57-0.81; SUCRA: 81.33%), underscoring its clinical significance over other effective agents such as albiglutide and semaglutide. Albiglutide, semaglutide, dulaglutide, and liraglutide also provided significant benefits, albeit with lower rankings. No major inconsistency or publication bias was detected. In conclusion, this NMA reinforces the class-wide cardiorenal benefits of GLP-1 receptor agonists while emphasizing variations in efficacy among individual agents, the limited evidence base for certain drugs, and the need for future head-to-head trials specifically designed to evaluate cardiovascular and renal endpoints."

Journal • Retrospective data • Review • Cardiovascular • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Efficacy and safety of glucagon-like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: An umbrella review and evidence map of randomised controlled trials. (PubMed, Diabetes Obes Metab) - "In this study, GLP-1RAs were associated with cardiovascular, renal, and metabolic benefits in type 2 diabetes without increasing cancer risk, though gastrointestinal adverse events were common. Our findings support the clinical use of GLP-1RAs, with attention to individual risk profiles and treatment tolerability."

HEOR • Journal • Cardiovascular • Congestive Heart Failure • Constipation • Diabetes • Dyspepsia • Gastroenterology • Gastrointestinal Cancer • Gastrointestinal Disorder • Heart Failure • Metabolic Disorders • Myocardial Infarction • Oncology • Peripheral Arterial Disease • Renal Disease • Type 2 Diabetes Mellitus

Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Dementia Risk in Type 2 Diabetes: A Comprehensive Bayesian Network Meta-Analysis (AHA 2025) - "For all-cause dementia versus control according to the SUCRA: albiglutide (RR: 0.03, 95% CrI: 0.00 to 0.08; SUCRA: 94.4%), lixisenatide (RR: 0.08, 95% CrI: 0.00 to 0.20; SUCRA: 93.62%), efpeglenatide (RR: 0.24, 95% CrI: 0.00 to 1.38; SUCRA: 70.09%), canagliflozin (RR: 0.31, 95% CrI: 0.01 to 1.47; SUCRA: 61.81%), semaglutide (RR: 0.50, 95% CrI: 0.03 to 1.98; SUCRA: 50.06%), liraglutide (RR: 2.12, 95% CrI: 0.02 to 9.89; SUCRA: 41.91%), empagliflozin (RR: 0.68, 95% CrI: 0.05 to 2.35; SUCRA: 39.63%), exenatide (RR: 4.13, 95% CrI: 0.02 to 20.28; SUCRA: 35.41%), dulaglutide (RR: 3.38, 95% CrI: 0.03 to 15.72; SUCRA: 32.89%), dapagliflozin (RR: 1.19, 95% CrI: 0.09 to 4.96; SUCRA: 30.37%), ertugliflozin (RR: 6.79, 95% CrI: 0.02 to 29.23; SUCRA: 30.1%), control (SUCRA: 19.67%). GLP-1RAs and SGLT2is reduce dementia risk, with albiglutide and lixisenatide excelling for all-cause dementia, dapagliflozin and ertugliflozin for vascular dementia, and dulaglutide for Alzheimer's...."

Retrospective data • Alzheimer's Disease • Cardiovascular • CNS Disorders • Dementia • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Dietary Intake in People Using Glucagon-Like-Receptor Agonists (OBESITY WEEK 2025) - "GLP-1 medication data was collected prior to approval of newer GLP-1s indicated for weight management and included lixisenatide (0.8%), albiglutide (2.4%), semaglutide (5.5%), dulaglutide (19.7%), exenatide (28.3%), and liraglutide (43.3%). People using GLP-1s had more significant nutrient gaps in fiber, copper, niacin, and iron compared to people not using GLP-1s. More than 45% of the people surveyed using GLP-1s did not meet recommended intakes for protein and several essential nutrients. Because this study was limited to analysis of mostly older generation GLP-1s, more data is needed to assess dietary intake using the newer generation of GLP-1s indicated for weight loss where energy intake is significantly impacted."

Metabolic Disorders

A Closer Look at FDA Trials: Safety and Efficacy of GLP-1 vs Non-GLP-1 for Obesity and Diabetes (OBESITY WEEK 2025) - " We reviewed US FDA Medical and Statistical reports (https://www.accessdata.fda.gov/), focusing on approved GLP-1 weight loss (WM) drugs liraglutide, semaglutide, tirzepatide, and non-GLP-1 agents orlistat, phentermine/topiramate. We also reviewed GLP-1 type 2 diabetes (T2D) drugs semaglutide, tirzepatide, exenatide, lixisenatide, albiglutide... This review of FDA medical and statistical reports suggests that GLP-1 agents, when compared to non-GLP-1 medications for weight management and to placebo in both weight loss and Type 2 diabetes trials, are associated with comparable or lower mortality rates and greater weight reduction. Mortality per patient-exposure year was consistently lower in treatment groups receiving GLP-1 agents. Weight loss outcomes were also more pronounced with GLP-1 therapies across indications."

Clinical • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

GLP-1 Receptor Agonists and Clinical Outcomes in Non-Diabetic Patients with Peripartum Cardiomyopathy: A Propensity-Matched Retrospective Cohort Study (AHA 2025) - "Patients prescribed GLP-1 RAs (liraglutide, semaglutide, exenatide, dulaglutide, lixisenatide, albiglutide) were compared to GLP-1-naïve PPCM controls. In this large real-world cohort of non-diabetic PPCM patients, GLP-1 RA use was associated with reduced heart failure events, improved LVEF, and better survival over 5 years without increased adverse events. These findings support further investigation into GLP-1 RAs as a potential cardioprotective therapy in PPCM."

Clinical data • Retrospective data • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Metabolic Disorders • Myocardial Infarction • Pancreatitis

Polygenic Modification of Weight Loss Response to GLP-1 Receptor Agonists (AHA 2025) - "Polygenic risk scores (PRS) summarize genetic susceptibility to obesity and predict weight trajectories, but their role in modifying GLP-1 RA treatment responses is unclear.MethodsUsing data from the of the nationwide NIH All of Us study, we matched participants prescribed any GLP-1RA (Albiglutide, Dulaglutide, Exenatide, Liraglutide, Lixisenatide, Semaglutide, Tirzepatide) to untreated participants in a 1:5 ratio by time at treatment, sex, age, education, income, deprivation index, and baseline weight...There was also a significant PRS × treatment interaction (β = -0.38 kg excess weight loss per BMI PRS SD; P=0.02).ConclusionGLP-1RA treatment led to greater weight loss in those with higher obesity PRS, suggesting enhanced benefit among genetically susceptible individuals. These findings support integrating PRS into personalized obesity treatment strategies."

Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

GLP-1 Analogues and Cardiovascular Outcomes in Heart Failure Patients: A Network Meta-Analysis (AHA 2025) - "A pairwise network meta-analysis using a random effects model compared GLP-1 RAs (Albiglutide, Dulaglutide, Exenatide, Liraglutide, Lixisenatide, Semaglutide, Tirzepatide) to placebo, assessing relative risk and P-scores for efficacy ranking was performed on R programming.Twelve randomized controlled trials with 15,761 heart failure patients were included (mean age 64 years, follow-up 24-280 weeks).For MACE, no drug showed a significant effect. In HF patients, GLP-1 RAs differ in their cardiovascular benefit profiles. Tirzepatide demonstrated maximum benefit in reducing HF hospitalizations, and Semaglutide showed promising results in lowering CV mortality; however no therapy appeared to be effective for MACE. These findings support personalized GLP-1 RAs selection based on patient-specific cardiovascular risk profiles and treatment priorities in comprehensive heart failure management."

Retrospective data • Cardiovascular • Congestive Heart Failure • Heart Failure

Glucagon-Like Peptide-1 Receptor Agonists Show Varied Impact on Venous Thromboembolism Risk: A Comprehensive Bayesian Network Meta-Analysis of Randomized Controlled Trials (AHA 2025) - "GLP-1RAs exhibit varied VTE risks, with liraglutide showing the highest risk for VTE, and albiglutide for PE. Dulaglutide and lixisenatide appear safer for DVT and PE, respectively."

Retrospective data • Cardiovascular • Diabetes • Hematological Disorders • Metabolic Disorders • Respiratory Diseases • Venous Thromboembolism

Comparative Risk of Acute Pancreatitis in Hypertriglyceridemia Patients Treated With SGLT2 Inhibitors vs GLP-1 Receptor Agonists: A Propensity-Score Matched Analysis (ACG 2025) - "In propensity-score–matched cohorts of 22,042 patients per arm, the incidence of acutepancreatitis was higher in patients treated with SGLT2 inhibitors compared to GLP-1receptor agonists, acute pancreatitis occurred in 0.349% of the SGLT2 users versus0.263% of the GLP-1 RA(OR 1.33, 95% CI 0.95–1.87; P = 0.10).In a multivariable Cox regression analysis adjusting for individual medications, For SGLT2inhibitors, the adjusted hazard ratios were: canagliflozin (aHR < 0.0001, 95% CI 0–0; P =0.9844), dapagliflozin (aHR 1.22, 95% CI 0.45–3.28; P = 0.6982), empagliflozin (aHR 0.77, 95%CI 0.34–1.73; P = 0.5249), and ertugliflozin (aHR < 0.0001, 95% CI 0–0; P = 0.9954). ForGLP-1 receptor agonists, results included: albiglutide (aHR < 0.0001, 95% CI 0–0; P = 0.9962),dulaglutide (aHR 1.19, 95% CI 0.63–2.25; P = 0.5968), semaglutide (aHR 1.58, 95% CI0.81–3.10; P = 0.1808), liraglutide (aHR 0.59, 95% CI 0.24–1.45; P = 0.2501), and exenatide(aHR 0.30, 95% CI 0.04–2.17; P =..."

Clinical • Cardiovascular • Dyslipidemia • Hypertriglyceridemia • Pancreatitis

Comparative Risk of Small Intestinal Bacterial Overgrowth (SIBO) Among Patients Using GLP-1 Receptor Agonists: A Real-World Analysis Using TriNetX (ACG 2025) - "Intermediate risks were observed for exenatide (0.048%), dulaglutide (0.047%), liraglutide (0.055%), and lixisenatide (0.073%)... A total of 2,305,630 patients were analyzed. The incidence of SIBO varied across the different GLP-1 receptor agonist agents. Albiglutide demonstrated the highest risk (0.156%), while tirzepatide showed the lowest (0.022%)."

Clinical • Real-world • Real-world evidence • Gastrointestinal Disorder • Metabolic Disorders

Comparative Risk of Pancreatic Pseudocyst Among Users of GLP-1 RAs: Findings From a Large-Scale EHR-Based Study (ACG 2025) - "Adult patients 18- 90 years with at least 6 months of GLP-1 RA exposure prescribed for diabetes, obesity, PCOS, metabolic syndrome or weight loss... Among 2,666,800 patients, the overall risk of developing a pancreatic pseudocyst was low, with notable variation by specific medication. Tirzepatide was associated with the lowest observed risk at 0.143% (737 cases among 516,978 patients), followed by semaglutide at 0.334% (3,817/1,142,264), dulaglutide at 0.605% (3,243/536,042), liraglutide at 0.723% (2,479/342,996), lixisenatide at 0.755% (114/15,097), exenatide at 0.935% (990/105,875), and albiglutide at 0.941% (71/7,548). Patients on newer agents (semaglutide, tirzepatide) demonstrated a substantially lower risk of pseudocyst formation compared to those on older agents (albiglutide, exenatide)."

Cardiovascular • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Pancreatitis • Polycystic Ovary Syndrome • Type 2 Diabetes Mellitus

COMPARATIVE EVALUATION OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS AND THEIR ASSOCIATION WITH THE RISK OF ASTHMA INCIDENCE: A COMPREHENSIVE BAYESIAN NETWORK META-ANALYSIS (CHEST 2025) - "For the reduction of asthma incidence, Semaglutide ranked highest (RR: 0.20, 95% CrI: 0.01 to 2.08; SUCRA: 84.83%), compared to Control (SUCRA: 44.9%), with Liraglutide ranked second (RR: 0.55, 95% CrI: 0.08 to 4.07; SUCRA: 64.4%). Other interventions included Exenatide (RR: 0.56, 95% CrI: 0.07 to 4.57; SUCRA: 63.57%), Lixisenatide (RR: 0.56, 95% CrI: 0.06 to 5.00; SUCRA: 63.08%), Cotadutide (RR: 0.81, 95% CrI: 0.05 to 39.67; SUCRA: 50.67%), Efpeglenatide (RR: 1.08, 95% CrI: 0.09 to 16.37; SUCRA: 43.95%), Dulaglutide (RR: 1.52, 95% CrI: 0.20 to 11.46; SUCRA: 32.65%), Albiglutide (RR: 1.77, 95% CrI: 0.24 to 12.90; SUCRA: 28.16%) and Tirzepatide (RR: 2.81, 95% CrI: 0.18– 115.35; SUCRA: 23.77%)... In conclusion, our Bayesian network meta-analysis demonstrates that Semaglutide is the most effective GLP-1 receptor agonist in reducing asthma incidence in patients with type 2 diabetes. In contrast, Tirzepatide and Albiglutide were associated with an increased risk of asthma...."

Retrospective data • Asthma • Diabetes • Immunology • Inflammation • Metabolic Disorders • Respiratory Diseases • Type 2 Diabetes Mellitus

GLP-1 RECEPTOR AGONISTS AND RISK OF VENOUS THROMBOEMBOLISM AND PULMONARY EMBOLISM IN TYPE 2 DIABETES: EVIDENCE FROM A LARGE, REAL-WORLD DATABASE ANALYSIS (CHEST 2025) - "Patients were stratified into Group A (GLP-1 RA group) comprising patients using exenatide, liraglutide, dulaglutide or semaglutide, or Group B (non-GLP-1 RA group). The exclusion criteria included the diagnosis of type 1 diabetes mellitus or exposure to albiglutide... The use of GLP-1 RAs in patients with T2DM is associated with decreased risk of VTE or PE. CLINICAL IMPLICATIONS: Further research is necessary before this information can be employed in clinical practice."

Clinical • Real-world • Real-world evidence • Cardiovascular • Diabetes • Metabolic Disorders • Respiratory Diseases • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus • Venous Thromboembolism

Exploring the neuroprotective role of GLP-1 agonists against Alzheimer's disease: Real-world evidence from a propensity-matched cohort. (PubMed, J Alzheimers Dis Rep) - "Adults aged ≥50 were included, comparing GLP-1RA users (liraglutide, semaglutide, dulaglutide, exenatide, albiglutide) to non-users. Dementia incidence was lower in GLP-1RA users (0.20% versus 0.44%), with a hazard ratio of 0.30 (95% CI 0.28-0.33; p < 0.001). GLP-1RA use was associated with a 70% reduced dementia risk, warranting further clinical evaluation."

HEOR • Journal • Real-world evidence • Alzheimer's Disease • CNS Disorders • Dementia • Diabetes • Inflammation • Metabolic Disorders • Type 2 Diabetes Mellitus

Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH) (clinicaltrials.gov) - P=N/A | N=23280000 | Active, not recruiting | Sponsor: Ohio State University

Heterogeneity • New trial • Real-world evidence • Cardiovascular • Metabolic Disorders

Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare. (PubMed, World J Cardiol) - "The GLP-1 receptor agonists (GLP-1RAs), namely liraglutide, dulaglutide, albiglutide, exenatide, and semaglutide, have been found to have beneficial effects on glycated hemoglobin, weight, lipid profile, and liver fat and thereby improving cardiometabolic health. Other drugs of the same group in development include Orforglipron, which has a high weight loss efficacy (-15% weight reduction). Long-acting GLP-1RAs in trials are Ecnoglutide, Efpeglenatide, TG103, and Visepegenatide...Retatrutide and Efocipegtrutide belong to this novel group of drugs. The newer drugs in the broad category of incretin co-agonists include the GLP-1/amylin receptor agonist like CagriSema and Amycretin, oral GLP-1 agonists other than semaglutide, and the peptide YY/GLP-1 receptor dual agonists. The profound biochemical and weight loss outcomes associated with incretin co-/poly-agonists are expected to translate into outstanding cardiometabolic benefits, the theme of this evidence review."

Journal • Review • Cardiovascular • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,592 patients. (PubMed, J Am Coll Cardiol) - "GLP-1 RAs reduce mortality and MACE in high-risk populations, highlighting benefits beyond glycemic control. These come at increased GI and gallbladder risks. Variation in efficacy and tolerability supports tailoring GLP-1 RA therapy to individual patient characteristics and treatment goals."

Journal • Retrospective data • Acute Kidney Injury • Cardiovascular • Congestive Heart Failure • Diabetes • Genetic Disorders • Heart Failure • Infectious Disease • Metabolic Disorders • Myocardial Infarction • Nephrology • Obesity • Oncology • Pancreatic Cancer • Pancreatitis • Renal Disease

An Insight into Pharmaceutical Design and Pharmacokinetic Characteristics of GLP-1 RAs. (PubMed, Curr Pharm Des) - "GLP-1 RAs have a complex strategy due to their pharmacological nature. The variations in their design have led to various members with varying pharmacodynamic and pharmacokinetic features."

Journal • PK/PD data • Cardiovascular • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

The effects of GLP-1 agonists on HbA1c and insulin dose among patients with type 1 diabetes. (PubMed, Front Endocrinol (Lausanne)) - "The keywords used were GLP-1 agonists, liraglutide, albiglutide, exenatide, glycated hemoglobin, HbA1c, insulin dose, and glycemic control. GLP-1 agonists were effective in HbA1c and total daily insulin reduction among patients with T1DM. Liraglutide 1.2 mg may be more beneficial; further randomized trials focusing on different doses of GLP-1 agonists and hypoglycemia risk are recommended."

Clinical • Journal • Review • Diabetes • Hypoglycemia • Metabolic Disorders • Type 1 Diabetes Mellitus

Disparities in GLP-1 receptor agonist prescriptions among breast cancer survivors with type 2 diabetes. (ASCO 2025) - "The primary outcome was the rate of GLP-1RA prescription (lixisenatide, albiglutide, dulaglutide, semaglutide, liraglutide, exenatide, tirzepatide). Significant disparities in GLP-1RA prescription rates were identified among breast cancer survivors with DM2, particularly among older adults and non-White racial groups. This emphasizes the need for targeted interventions to improve equitable access to these classes of pharmaceutics with important health benefits in cancer survivors. Table 1: GLP-1RA Prescription Disparities by Racial Subgroups"

Breast Cancer • Coronary Artery Disease • Diabetes • Dyslipidemia • Endocrine Cancer • Gastrointestinal Disorder • Genetic Disorders • Heart Failure • Hypertension • Metabolic Disorders • Obesity • Obstructive Sleep Apnea • Oncology • Pancreatic Cancer • Pancreatitis • Respiratory Diseases • Sleep Disorder • Solid Tumor • Thyroid Gland Carcinoma • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

GLP1 RECEPTOR AGONISTS AND HEPATIC DECOMPENSATION IN PATIENTS WITH MASH CIRRHOSIS: A PROPENSITY-MATCHED ANALYSIS OF THE US COLLABORATIVE NETWORK (DDW 2025) - "We constructed 1-1 propensity-score (PS)-matched cohorts of patients initiating GLP-1RAs (semaglutide, liraglutide, exenatide, dulaglutide, albiglutide, tirzepatide, or lixisenatide) or DPP-4 inhibitors (alogliptin, linagliptin, saxagliptin or sitagliptin). In patients with compensated MASH cirrhosis, GLP-1RAs were associated with significantly lower rates of hepatic decompensation and all-cause mortality compared to DPP-4 inhibitors. These findings suggest a potential therapeutic benefit of GLP-1RAs in this population, warranting further validation through prospective studies."

Clinical • CNS Disorders • Diabetes • Fibrosis • Genetic Disorders • Hematological Disorders • Hepatic Encephalopathy • Hepatocellular Cancer • Hepatology • Immunology • Liver Failure • Metabolic Dysfunction-Associated Steatohepatitis • Nephrology • Obesity • Oncology • Renal Disease • Solid Tumor

Risk of Cutaneous Adverse Drug Reactions with GLP-1 Receptor Agonists: Insights from FAERS and Systematic Review (ISPOR 2025) - "Liraglutide was linked to injection site urticaria (n=197; PRR=6.0; chisq=797.6), dulaglutide to injection site hypersensitivity (n=61; PRR=8.4; chisq=373.4), and albiglutide to injection site rash (n=43; PRR=12.8; chisq=454.2)...Dulaglutide was the most frequently implicated drug, followed by exenatide and liraglutide. Findings from the FAERS database and systematic review demonstrate a significant association between GLP-1 RAs and CADRs, ranging from localized to rare systemic reactions. Carefully monitoring CADRs in patients using GLP-1 RAs is essential to optimizing treatment safety, improving outcomes, and ensuring the overall well-being of patients undergoing this therapy."

Adverse drug reaction • Review • Bullous Pemphigoid • Cardiovascular • Dermatology • Dermatopathology • Diabetes • Genetic Disorders • Immunology • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus • Urticaria • Vasculitis

Exploring Glucagon-Like Peptide-1 Receptor Agonists Usage Among Non-Diabetic Healthcare Providers: A Cross-Sectional Multi-Country Study. (PubMed, Health Sci Rep) - "Semaglutide (45.7%, 95% CI: 41.8%-49.5%) was the most commonly used GLP-1RA, followed by Liraglutide (36.9%, 95% CI: 33.2%-40.8%). Other GLP-1RAs were used less frequently, including Dulaglutide (17.0%, 95% CI: 14.2%-20.1%), Exenatide (14.1%, 95% CI: 11.5%-17.0%), Albiglutide (7.0%, 95% CI: 5.1%-9.2%), and Lixisenatide (8.5%, 95% CI: 6.5%-10.9%...This study provides the first prevalence estimate of GLP-1RA use among HCPs and GLP1-Ras users and explores the associations between demographic characteristics and perceptions of safety and efficacy. The findings highlight the self-prescribing practices of these medications for weight management and underscore the need for appropriate monitoring to avoid potential health risks."

Journal • Genetic Disorders • Metabolic Disorders • Type 2 Diabetes Mellitus